

参考文献

- Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). *J Antimicrob Chemother.* 2019;74(3):739-745.
- Kityo C, Hagins D, Koenig E, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial. *J Acquir Immune Defic Syndr.* 2019;82(3):321-328.
- Kozal M, et al. Fostemsavir in adults with multidrug-resistant HIV-1 infection. *N Engl J Med.* 2020;382(13):1232-1243.
- Kumar P, Johnson M, Xu ZJ, et al. Weight changes after switch to doravirine/lamivudine/TDF in the DRIVE-SHIFT trial. *J Int AIDS Soc.* 2020;23(suppl 4):26-27. Abstract OAB0605.
- Lataillade M, Lalezari J, Aberg J, et al. Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug resistant HIV-1 (BRIGHT study). 10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City. Abstract MOAB0102.
- Lathouwers E, De Meyer S, Dierynck I, et al. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. *Antivir Ther.* 2011;16:99-108.
- Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. *Lancet.* 2018 Mar 3;391(10123):839-849.
- Maggiolo F, Gulminetti R, Pagnucco L, et al. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. *BMC Infect Dis.* 2017;17(1):215.
- Mallolas J, Podzamczar D, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: The ATAZIP study. *J Acquir Immune Defic Syndr.* 2009;51:29-36.
- Mallon P, Brunet L, Hsu R, et al. Weight gain before and after switch from TDF to TAF. *J Int AIDS Soc.* 2020;23(suppl 4):25-26. Abstract OAB0604.
- Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: A randomized, 96-week trial. *Clin Infect Dis.* 2009;49:1591-1601.